Drug Information

Back

Matulane

Brand Name:	Matulane	Trade Name:	procarbazine
FDA Approved For:	Matulane is indicated for use in combination with other anticancer drugs for the treatment of Stage III and IV Hodgkin's disease. Matulane is used as part of the MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) regimen.	Pediatric Use:	Very close clinical monitoring is mandatory. Undue toxicity, evidenced by tremors, coma and convulsions, has occurred in a few cases. Dosage, therefore, should be individualized.
Carcinogen:	The carcinogenicity of procarbazine hydrochloride in mice, rats and monkeys has been reported in a considerable number of studies. Instances of a second nonlymphoid malignancy, including acute myelocytic leukemia, have been reported in patients with Hodgkin's disease treated with procarbazine in combination with other chemotherapy and/or radiation. The International Agency for Research on Cancer (IARC) considers that there is "sufficient evidence" for the human carcinogenicity of procarbazine hydrochloride when it is given in intensive regimens which include other antineoplastic agents but that there is inadequate evidence of carcinogenicity in humans given procarbazine hydrochloride alone.	Mutagen:	Procarbazine hydrochloride has been shown to be mutagenic in a variety of bacterial and mammalian test systems.
Manufacturer and/or Distributor:	Sigma Tau Pharms

Adverse Reactions:

Leukopenia, anemia and thrombopenia occur frequently. Nausea and vomiting are the most commonly reported side effects. Other adverse reactions are: Hematologic: Pancytopenia; eosinophilia; hemolytic anemia; bleeding tendencies such as petechiae, purpura, epistaxis and hemoptysis. Gastrointestinal: Hepatic dysfunction, jaundice, stomatitis, hematemesis, melena, diarrhea, dysphagia, anorexia, abdominal pain, constipation, dry mouth. Neurologic: Coma, convulsions, neuropathy, ataxia, paresthesia, nystagmus, diminished reflexes, falling, foot drop, headache, dizziness, unsteadiness. Cardiovascular: Hypotension, tachycardia, syncope. Ophthalmic: Retinal hemorrhage, papilledema, photophobia, diplopia, inability to focus. Respiratory: Pneumonitis, pleural effusion, cough. Dermatologic: Herpes, dermatitis, pruritus, alopecia, hyperpigmentation, rash, urticaria, flushing. Allergic: Generalized allergic reactions. Genitourinary: Hematuria, urinary frequency, nocturia. Musculoskeletal: Pain, including myalgia and arthralgia; tremors. Psychiatric: Hallucinations, depression, apprehension, nervousness, confusion, nightmares. Endocrine: Gynecomastia in prepubertal and early pubertal boys. Miscellaneous: Intercurrent infections, hearing loss, pyrexia, diaphoresis, lethargy, weakness, fatigue, edema, chills, insomnia, slurred speech, hoarseness, drowsiness. Second nonlymphoid malignancies, including acute myelocytic leukemia and malignant myelosclerosis, and azoospermia have been reported in patients with Hodgkin's disease treated with procarbazine in combination with other chemotherapy and/or radiation. )

More Information

Back